Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.

Journal: Journal Of The National Comprehensive Cancer Network : JNCCN
Published:
Abstract

Differentiated thyroid carcinomas is associated with an excellent prognosis. The treatment of choice for differentiated thyroid carcinoma is surgery, followed by radioactive iodine ablation (iodine-131) in select patients and thyroxine therapy in most patients. Surgery is also the main treatment for medullary thyroid carcinoma, and kinase inhibitors may be appropriate for select patients with recurrent or persistent disease that is not resectable. Anaplastic thyroid carcinoma is almost uniformly lethal, and iodine-131 imaging and radioactive iodine cannot be used. When systemic therapy is indicated, targeted therapy options are preferred. This article describes NCCN recommendations regarding management of medullary thyroid carcinoma and anaplastic thyroid carcinoma, and surgical management of differentiated thyroid carcinoma (papillary, follicular, Hürthle cell carcinoma).

Authors
Robert Haddad, Lindsay Bischoff, Douglas Ball, Victor Bernet, Erik Blomain, Naifa Busaidy, Michael Campbell, Paxton Dickson, Quan-yang Duh, Hormoz Ehya, Whitney Goldner, Theresa Guo, Megan Haymart, Shelby Holt, Jason Hunt, Andrei Iagaru, Fouad Kandeel, Dominick Lamonica, Susan Mandel, Stephanie Markovina, Bryan Mciver, Christopher Raeburn, Rod Rezaee, John Ridge, Mara Roth, Randall Scheri, Jatin Shah, Jennifer Sipos, Rebecca Sippel, Cord Sturgeon, Thomas Wang, Lori Wirth, Richard Wong, Michael Yeh, Carly Cassara, Susan Darlow

Similar Publications